Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | fatty-acid desaturase, putative | 0.0459 | 1 | 1 |
Schistosoma mansoni | fatty acid desaturase | 0.0244 | 0.2339 | 0.5 |
Loa Loa (eye worm) | FAT-3 protein | 0.0243 | 0.2317 | 0.3024 |
Onchocerca volvulus | 0.0459 | 0.9978 | 1 | |
Brugia malayi | acyl-CoA desaturase | 0.0393 | 0.7661 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0243 | 0.2317 | 0.3024 |
Loa Loa (eye worm) | acyl-CoA desaturase | 0.0393 | 0.7661 | 1 |
Trypanosoma cruzi | fatty acid desaturase, putative | 0.0459 | 1 | 1 |
Plasmodium falciparum | stearoyl-CoA desaturase | 0.0393 | 0.7661 | 0.5 |
Plasmodium vivax | stearoyl-CoA desaturase (acyl-CoA desaturase, faty acid desaturase), putative | 0.0393 | 0.7661 | 0.5 |
Onchocerca volvulus | 0.0459 | 0.9978 | 1 | |
Trypanosoma brucei | fatty acid desaturase, putative | 0.0459 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | = 0.9 uM | Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay | ChEMBL. | 19715319 |
GI50 (functional) | = 1 uM | Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay | ChEMBL. | 19715319 |
GI50 (functional) | = 1.5 uM | Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay | ChEMBL. | 19715319 |
GI50 (functional) | = 1.7 uM | Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay | ChEMBL. | 19715319 |
GI50 (functional) | = 2.7 uM | Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay | ChEMBL. | 19715319 |
GI50 (functional) | = 3.3 uM | Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay | ChEMBL. | 19715319 |
GI50 (functional) | > 10 uM | Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay | ChEMBL. | 19715319 |
IC50 (functional) | = 3.3 uM | Cytotoxicity against human A2780 cells after 48 hrs by MTT assay | ChEMBL. | 19715319 |
IC50 (functional) | = 3.6 uM | Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay | ChEMBL. | 19715319 |
IC50 (functional) | = 4.1 uM | Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay | ChEMBL. | 19715319 |
IC50 (functional) | = 4.7 uM | Cytotoxicity against human KB cells after 48 hrs by MTT assay | ChEMBL. | 19715319 |
IC50 (functional) | = 5 uM | Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay | ChEMBL. | 19715319 |
IC50 (functional) | = 5.4 uM | Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay | ChEMBL. | 19715319 |
IC50 (functional) | = 7 uM | Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay | ChEMBL. | 19715319 |
IC50 (functional) | = 9.9 uM | Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay | ChEMBL. | 19715319 |
IC50 (functional) | > 10 uM | Cytotoxicity against human U937 cells expressing p53 mutant after 48 hrs by SRB assay | ChEMBL. | 19715319 |
IC50 (functional) | > 10 uM | Cytotoxicity against human THP1 cells expressing p53 mutant after 48 hrs by SRB assay | ChEMBL. | 19715319 |
IC50 (functional) | > 10 uM | Cytotoxicity against p53-deficient human K562 cells after 48 hrs by SRB assay | ChEMBL. | 19715319 |
IC50 (functional) | > 10 uM | Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay | ChEMBL. | 19715319 |
IC50 (functional) | = 10 uM | Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay | ChEMBL. | 19715319 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 19715319 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.